[1]赵崇山,王宁方,何文艳.脾脏硬度及细胞因子在原发性血小板增多症患者血栓预测中的价值[J].医学信息,2021,34(21):69.[doi:10.3969/j.issn.1006-1959.2021.21.017]
 ZHAO Chong-shan,WANG Ning-fang,HE Wen-yan.The Value of Spleen Stiffness Measurement and Cytokines in Predicting Thrombosis in Patients with Essential Thrombocytosis[J].Medical Information,2021,34(21):69.[doi:10.3969/j.issn.1006-1959.2021.21.017]
点击复制

脾脏硬度及细胞因子在原发性血小板增多症患者血栓预测中的价值()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年21期
页码:
69
栏目:
论著
出版日期:
2021-11-01

文章信息/Info

Title:
The Value of Spleen Stiffness Measurement and Cytokines in Predicting Thrombosis in Patients with Essential Thrombocytosis
文章编号:
1006-1959(2021)21-0069-04
作者:
赵崇山王宁方何文艳
(河北中石油中心医院感染科1,血液科2,河北 廊坊 065000)
Author(s):
ZHAO Chong-shanWANG Ning-fangHE Wen-yan
(Department of Infection1,Department of Hematology2,Hebei Petro China Central Hospita,Langfang 065000,Hebei,China)
关键词:
原发性血小板增多症脾脏硬度细胞因子
Keywords:
Essential thrombocytosisSpleen stiffness measurementCytokines
分类号:
R558.3
DOI:
10.3969/j.issn.1006-1959.2021.21.017
文献标志码:
A
摘要:
目的 探讨脾脏硬度(SSM)及细胞因子在原发性血小板增多症(ET)患者血栓预测中应用。方法 选取2015年1月-2020年1月河北中石油中心医院就诊的50例初诊ET患者作为研究对象,根据有无血栓史分为有血栓史组和无血栓史组,比较两组一般资料及随访期间不同临床特征与无血栓生存期的关系。结果 19例既往有血栓病史,占比38.00%。有血栓组及无血栓组间年龄、心血管危险因素、危险度分级、JAK2/V617F、SSM、TNF-α比较,差异有统计学意义(P<0.05);有血栓组及无血栓史组间CALR-EXON9、WBC、Hb、PLT、IL-1、IL-6、IL-8比较,差异无统计学意义(P>0.05)。Kaplan-Meier生存分析显示,SSM>31 kPa患者TFS短于SSM≤31 kPa患者(29个月vs 53个月)、IL-1β>338.40 pg/ml患者TFS短于IL-1β≤338.40 pg/ml患者(36个月vs 50个月)、IL-6>215.35 pg/ml患者TFS短于IL-6≤215.35 pg/ml患者(35个月vs 50个月)、IL-8>660.10 pg/ml患者TFS短于IL-8≤660.10 pg/ml患者(35个月vs 53个月)、TNF-α>330.00 pg/ml患者TFS短于TNF-α≤330.00 pg/ml患者(28个月vs 51个月)、有血栓形成患者TFS短于无血栓形成患者(36个月 vs 未达到),差异有统计学意义(P<0.05)。结论 SSM、IL-1β、IL-6、IL-8、TNF-α与血栓形成密切相关,高SSM及高水平细胞因子可用来预测血栓形成,进一步指导抗凝治疗。
Abstract:
Objective To explore the value of spleen stiffness measurement (SSM) and cytokines in predicting thrombosis in patients with essential thrombocytosis(ET).Methods A total of 50 patients with newly diagnosed ET in Hebei Petro China Central Hospital from January 2015 to January 2020 were selected as the research subjects. According to the history of thrombosis, they were divided into thrombosis group and non-thrombosis group. The general data and the relationship among different clinical characteristics and non-thrombosis survival were compared between the two groups.Results A total of 19 cases had a history of thrombosis, accounting for 38.00%. There were statistically significant differences in age, cardiovascular risk factors, risk classification, JAK2/V617F, SSM and TNF-α between thrombosis group and non-thrombosis group (P<0.05); there was no significant difference in CALR-EXON9, WBC, Hb, PLT, IL-1, IL-6 and IL-8 between thrombosis group and non-thrombosis group (P>0.05). Kaplan-Meier survival analysis showed that the TFS of patients with SSM>31 kPa was shorter than that of patients with SSM≤31 kPa (29 months vs 53 months), the TFS of patients with IL-1β>338.40 pg/ml was shorter than that of patients with IL-1β≤338.40 pg/ml (36 months vs 50 months), the TFS of patients with IL-6>215.35 pg/ml was shorter than that of patients with IL-6≤215.35 pg/ml (35 months vs 50 months), the TFS of patients with IL-8>660.10 pg/ml was shorter than that of patients with IL-8≤660.10 pg/ml (35 months vs 53 months), and the TFS of patients with TNF-α>330.00 pg/ml was shorter than that of patients with TNF-α≤330.00 pg/ml (28 months vs 51 months).Conclusion SSM, IL-1β, IL-6, IL-8 and TNF-α are closely related to thrombosis. High SSM and high-level cytokines can be used to predict thrombosis and further guide anticoagulant therapy.

参考文献/References:

[1]Wong GL,Liang LY,Kwok R,et al.Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness[J].Hepatology,2019,70(3):971-981.[2]Iurlo A,Cattaneo D,Giunta M,et al.Reply To: Assessment of Liver and Spleen Stiffness in Patients With Myelofibrosis Using FibroScan and Shear Wave Elastography[J].Ultrasound Q,2016,32(3):317.[3]Febvre-James M,Lecureur V,Augagneur Y,et al.Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages[J].Int Immunopharmacol,2018(54):354-365.[4]Isaksson HS,Farkas SA,Müller P,et al.Whole genome microarray expression analysis in blood identifies pathways linked to signs and symptoms of a patient with hypercalprotectinaemia and hyperzincaemia[J].Clin Exp Immunol,2018,191(2):240-251.[5]Vainchenker W,Kralovics R.Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms[J].Blood,2017,129(6):667-679.[6]Wang Y,Zuo X.Cytokines frequently implicated in myeloproliferative neoplasms[J].Cytokine X,2019,1(1):100005.[7]Joseph L,Fink LM,Hauer-Jensen M.Cytokines in coagulation and thrombosis: a preclinical and clinical review[J].Blood Coagul Fibrinolysis,2002,13(2):105-116.[8]Du T,Tan Z.Relationship between deep venous thrombosis and inflammatory cytokines in postoperative patients with malignant abdominal tumors[J].Braz J Med Biol Res,2014,47(11):1003-1007.[9]肖志坚.真性红细胞增多症诊断与治疗中国专家共识(2016年版)[J].中华血液学杂志,2016,37(4):265-268.[10]Arber DA,Orazi A,Hasserjian R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127(20):2391-2405.[11]岳岑,吴升彬,马琪林.早期进展性脑梗死患者血清HINGBI、TNF-α水平动态变化及意义[J].中外医学研究,2018,16(24):53-55.[12]Kandabashi T,Shimokawa H,Miyata K,et al.Evidence for protein kinase C-mediated activation of Rho-kinase in a porcine model of coronary artery spasm[J].Arterioscler Thromb Vasc Biol,2003,23(12):2209-2214.[13]Westerterp M,Fotakis P,Ouimet M,et al.Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis[J].Circulation,2018,138(9):898-912. [14]van der Poll T,Levi M,Hack CE,et al.Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees[J].J Exp Med,1994(179):1253-1259.[15]Wojcik BM,Wrobleski SK,Hawley AE,et al.Interleukin-6: a potential target for post-thrombotic syndrome[J].Ann Vasc Surg,2011(25):229-239.[16]Wu J,Zhu H,Yang G,et al.IQCA-TAVV: To explore the effect of P-selectin, GPIIb/IIIa, IL-2, IL-6 and IL-8 on deep venous thrombosis[J].Oncotarget,2017,8(53):91391-91401.

相似文献/References:

[1]吴 双,王春森.费城染色体阴性骨髓增殖性肿瘤体细胞突变的研究现状[J].医学信息,2021,34(02):59.[doi:10.3969/j.issn.1006-1959.2021.02.017]
 WU Shuang,WANG Chun-sen.Research Status of Somatic Mutation in Philadelphia Chromosome-negative Myeloproliferative Neoplasms[J].Medical Information,2021,34(21):59.[doi:10.3969/j.issn.1006-1959.2021.02.017]
[2]赵崇山,王宁方.脾脏硬度联合流式细胞术在急性髓系白血病微小残留病监测中的意义[J].医学信息,2022,35(05):121.[doi:10.3969/j.issn.1006-1959.2022.05.031]
 ZHAO Chong-shan,WANG Ning-fang.The Significance of Spleen Stiffness Measurement Combine with Flow Cytometry in Acute Myeloid Leukemia Minimal Residual Disease[J].Medical Information,2022,35(21):121.[doi:10.3969/j.issn.1006-1959.2022.05.031]
[3]尹凤雷,许卫星,李淑晨,等.骨髓增殖性肿瘤中JAK2V617F突变与Ⅰ型细胞因子受体的相关性[J].医学信息,2022,35(06):97.[doi:10.3969/j.issn.1006-1959.2022.06.024]
 YIN Feng-lei,XU Wei-xing,LI Shu-chen,et al.Correlation Between JAK2V617F Mutation and Type Ⅰ Cytokine Receptor in Myeloproliferative Neoplasms[J].Medical Information,2022,35(21):97.[doi:10.3969/j.issn.1006-1959.2022.06.024]
[4]赵崇山,王宁方.脾脏硬度对初发骨髓增生异常综合征患者预后的影响[J].医学信息,2022,35(07):88.[doi:10.3969/j.issn.1006-1959.2022.07.021]
 ZHAO Chong-shan,WANG Ning-fang.Effect of Spleen Stiffness Measurement on Prognosis of Patients with Primary Myelodysplastic Syndrome[J].Medical Information,2022,35(21):88.[doi:10.3969/j.issn.1006-1959.2022.07.021]

更新日期/Last Update: 1900-01-01